Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 13,160,939	$ 13,359,615
Contracts and grants receivable	113,756	115,130
Research and development incentives receivable, current	25,284	104,198
Prepaid expenses and other current assets	171,327	274,209
Total current assets	13,471,306	13,853,152
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $118,141 and $114,766	15,106	18,481
Deferred issuance cost	17,867	20,206
Right-of-use lease assets	286,555	340,987
Research and development incentives receivable, net of current portion	12,642	24,114
Total assets	13,826,253	14,279,717
Current liabilities:
Accounts payable	2,472,327	3,865,796
Accrued expenses	2,346,361	2,307,746
Accrued compensation	73,861	336,692
Lease liabilities, current	115,221	108,948
Convertible debt, net of debt discount of $0 and $102,309	750,000	9,897,691
Total current liabilities	5,757,770	16,516,873
Non-current liabilities:
Convertible debt	2,094,000
Lease liabilities, net of current portion	174,283	233,627
Total liabilities	8,026,053	16,750,500
Commitments and contingencies
Series D preferred stock, $.001 par value; 0 and 50,000 shares authorized, none issued or outstanding as of June 30, 2023 and December 31, 2022, respectively		43
Shareholders' equity/(deficit):
Preferred stock, 350,000 and 300,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; none issued or outstanding	0	0
Common stock, $.001 par value; 75,000,000 shares authorized; 9,841,854 and 2,908,578 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	9,842	2,909
Additional paid-in capital	228,005,876	217,064,964
Accumulated other comprehensive income	6,061	24,747
Accumulated deficit	(222,221,579)	(219,563,446)
Total shareholders' equity/(deficit)	5,800,200	(2,470,826)
Total liabilities, mezzanine equity and shareholders' equity/(deficit)	$ 13,826,253	$ 14,279,717